drugset

drugset / Trial / NCT03046979

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

NCT03046979 ↗

Phase 2 Unknown 30 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.

Timeline

Start: 2016-12
Primary completion: 2017-12
Completion: 2018-12

Publications

Hou Z, Zhu K, Yang X, Chen P, Zhang W, Cui Y, Zhu X, Song T, Li Q, Li H, Zhang T. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. Ann Transl Med. 2020 Sep;8(17):1047. doi: 10.21037/atm-20-2990.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	500 mg	Oral

Indications